Le Lézard
Classified in: Health, Covid-19 virus
Subject: TRI

Edwards Pauses Enrollments In Pivotal Mitral, Tricuspid Trials In Response To Hospitals' Focus On COVID-19


IRVINE, Calif., March 28, 2020 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced it will temporarily pause new enrollments in its active pivotal clinical trials of transcatheter mitral and tricuspid therapies, in response to the urgent COVID-19 response around the globe.

Edwards is coordinating closely with the trials' clinical investigators, and the decision to resume enrollments in the trials will be made in consultation with each investigator and hospital at the time when their clinicians' and patients' needs can be better served.  The company continues to pursue its vision of transforming care for patients with mitral and tricuspid valvular disease by developing a portfolio of innovative therapies supported by a growing body of clinical evidence. 

With the virtual American College of Cardiology meeting underway today, analyses from the CLASP TR Early Feasibility Study are available at https://virtual.acc.org/.

About Edwards Lifesciences

Edwards Lifesciences, based in Irvine, Calif., is the global leader of patient-focused medical innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to continued portfolio development and coordination with investigators.  Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.  Statements of past performance, efforts, or results about which inferences or assumptions may be made can also be forward-looking statements and are not indicative of future performance or results; these statements can be identified by the use of words such as "continued," "transform," "develop," "preliminary," "initial," diligence," "industry-leading," "compliant," "indications," or "early feedback" or other forms of these words or similar words or expressions or the negative thereof.  Investors are cautioned not to unduly rely on such forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors, including but not limited to, the impacts of COVID-19, including, but not limited to, impacts to the economy, healthcare systems, travel, supply chains and the responsive actions of governments and other authorities. Other factors are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2019. These filings, along with important safety information about our products, may be found at edwards.com.

Edwards, Edwards Lifesciences, the stylized E logo and CLASP are trademarks of Edwards Lifesciences Corporation and its affiliates. All other trademarks are the property of their respective owners. This statement is made on behalf of Edwards Lifesciences Corporation and its subsidiaries.

SOURCE Edwards Lifesciences Corporation


These press releases may also interest you

at 13:01
Metabolomic Technologies Inc. (MTI) is excited to announce the national expansion of its proprietary and innovative test, PolypDxtm. This non-invasive, convenient urine test is a major breakthrough to detect adenomatous polyps and help prevent colon...

at 13:00
The "Anaerobic Digestion Deployment in the UK" report has been added to ResearchAndMarkets.com's offering. This 2020 edition of the annual report provides a comprehensive regional breakdown of sector development in Scotland, Wales, Northern Ireland,...

at 13:00
The Parenteral Drug Association (PDA) today announced the availability of a new website for the PDA Foundation, a 501(c)(3) nonprofit founded in 1997 to help support PDA and other industry activities. This new website makes it easier for industry...

at 12:48
- Curesponse is a cancer precision medicine company whose platform, cResponse, accurately and quickly predicts a patient's response to cancer treatment. - The company has raised $6M from investors including NCL Technology Ventures (UK) and aMoon...

at 12:25
Compassion & Choices today announced a historic collaboration with the Ventanillas de Salud (Windows of Health) network to launch a bilingual educational campaign during the COVID-19 crisis to inform U.S.-based Mexican immigrants about their full...

at 12:17
We know Canadians living with disabilities are facing significant challenges during this difficult time, with some experiencing job insecurity and others seeing increased costs for personal support workers, medication, and medical supplies. As we...



News published on 28 march 2020 at 10:00 and distributed by: